NRSN Latest Press Releases

-- March 9, 2026 --

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PRNewswire 11:08 AM

-- February 18, 2026 --

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS PRNewswire 9:05 AM

-- February 9, 2026 --

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition PRNewswire 9:20 AM

-- January 21, 2026 --

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PRNewswire 8:30 AM

-- January 8, 2026 --

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PRNewswire 8:45 AM

-- December 4, 2025 --

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PRNewswire 7:30 AM

-- November 24, 2025 --

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS PRNewswire 9:56 AM

-- November 3, 2025 --

NeuroSense to Host Investor Webinar on December 8, 2025 PRNewswire 9:15 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software